Opexa Therapeutics 4Q Loss Widens

The company lost $14.7 million, or $2.19 per share, compared with a loss of $12.6 million or $2.35 per share. The company had no revenue in 2007 or 2006. Opexa had about 1.3 million additional shares in 2007.

Opexa did not report fourth-quarter results.

Research and development expenses rose 70 percent to about $13.1 million, primarily due to midstage studies of the company's experimental multiple sclerosis treatment Tovaxin.